Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Aurelie Courtin"'
Autor:
Simon J. Cook, Richard Odle, Marc O'Reilly, Brent Graham, Aurelie Courtin, Emma Minihane, Kathryn Balmanno, Harpreet K. Saini, Joanne M. Munck, Andrew M. Kidger
The RAS-regulated RAF-MEK1/2-ERK1/2 signaling pathway is frequently deregulated in cancer due to activating mutations of growth factor receptors, RAS or BRAF. Both RAF and MEK1/2 inhibitors are clinically approved and various ERK1/2 inhibitors (ERKi)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f75a06a552ccae6e14211a5956c6395
https://doi.org/10.1158/1535-7163.c.6542839
https://doi.org/10.1158/1535-7163.c.6542839
Autor:
Simon J. Cook, Richard Odle, Marc O'Reilly, Brent Graham, Aurelie Courtin, Emma Minihane, Kathryn Balmanno, Harpreet K. Saini, Joanne M. Munck, Andrew M. Kidger
Supplementary Tables and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5109fc882ed9ce4603d93a4796b6f2f3
https://doi.org/10.1158/1535-7163.22520935.v1
https://doi.org/10.1158/1535-7163.22520935.v1
Autor:
Silvia Blacher, Carine Munaut, Agnès Noël, Aurelie Courtin, Mélanie Mestdagt, Jean-Michel Foidart, Laudine Communal, Céline Gérard, Ekaterine Tskitishvili, Anne Gompel, Christel Pequeux
Publikováno v:
The Journal of endocrinology. 224(1)
Estetrol (E4) is a natural estrogen produced exclusively by the human fetal liver during pregnancy. Its physiological activity remains unknown. In contrast to ethinyl estradiol and estradiol (E2), E4has a minimal impact on liver cell activity and cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f3971cfc06208c033ee87abf36738b
https://pubmed.ncbi.nlm.nih.gov/25359896
https://pubmed.ncbi.nlm.nih.gov/25359896
Autor:
Aurélie Courtin, Frances M Richards, Tashinga E Bapiro, Jo L Bramhall, Albrecht Neesse, Natalie Cook, Ben-Fillippo Krippendorff, David A Tuveson, Duncan I Jodrell
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67330 (2013)
Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the eff
Externí odkaz:
https://doaj.org/article/e84923692d2b48e9bbd3ce4de3f87151